Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shalit, I. Articles by Osherov, N. Search for Related Content PubMed PubMed Citation Articles by Shalit, I. Articles by Osherov, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1416-1418, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1416-1418.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Synergy of Caspofungin and Itraconazole against Aspergillus spp.: MIC versus Minimal Effective Concentration End Points

Itamar Shalit,^1,2 Yona Shadkchan,² Zmira Samra,^2,3 and Nir Osherov^2*

Schneider Children's Medical Center of Israel,¹ Sackler School of Medicine,² Rabin Medical Center, Petach Tikvah, Tel Aviv University, Tel Aviv, Israel³

Received 22 August 2002/ Returned for modification 28 October 2002/ Accepted 21 January 2003

Top Abstract Text References

 
Caspofungin and itraconazole were studied alone and in combination against 31 clinical isolates of Aspergillus spp. according to NCCLS M38-P guidelines. MICs and microscopic minimal effective concentrations (MECs) were recorded, and synergy was calculated by using both end points. Synergy or synergy to additivity was found in 30 of 31 isolates by using MIC end points. With MEC end points no synergy was found and indifference was detected in 26 of 31 strains.

Top Abstract Text References

 
Caspofungin is the first member of a new class of antifungal agents, the echinocandins, licensed for clinical use. It is indicated for the treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies (4). Aspergillosis remains a major cause of morbidity and mortality among immunocompromised hosts. Current therapeutic modalities, including the introduction of new agents, are still associated with significant mortality (9). Thus, any combination therapy that may enhance antifungal activity should be actively pursued. Caspofungin exerts its activity by inhibiting synthesis of 1,3-ß-D-glucan, an essential homopolysaccharide in the cell walls of many pathogenic fungi. This mode of activity is unique, making caspofungin a potential candidate for combination therapy with other classes of antifungal agents for the treatment of aspergillosis. Preliminary studies have shown in vitro synergy or additivity between caspofungin and amphotericin B against approximately 50% of Aspergillus spp. (2) and between caspofungin and amphotericin B or fluconazole against Cryptococcus neoformans (3). In the present study we performed in vitro synergy studies with caspofungin and itraconazole against isolates of Aspergillus species obtained from immunocompromised patients with invasive aspergillosis. In vitro activity of caspofungin against Aspergillus spp., as determined by using the NCCLS M38-P microdilution methodology, is characterized by a high MIC (>16 µg/ml) against most isolates (1, 2). In contrast, it was known that, since the introduction of the echinocandin cilofungin, much lower concentrations of members of this class of drugs lead to significant disruption of hyphae and to decreased turbidity and visual growth (5). These observations led to a new definition of minimal effective concentration (MEC) as the lowest concentration of drug causing abnormal growth characterized by short abundant branchings (2, 7). In the present study we analyzed synergy utilizing both MIC and MEC end points and compared the results obtained by both methods.

In vitro susceptibility and checkerboard assays were performed on 31 clinical isolates of Aspergillus (A. fumigatus [n = 13], A. niger [n = 6], A. flavus [n = 6], and A. terreus [n = 6]). Control strains (A. fumigatus strain AF293 and A. niger ATCC 16404) were tested in every experiment as internal controls. Caspofungin (Merck Research Laboratories, Rahway, N.J.) and itraconazole (Janssen Pharmaceutica, Titusville, N.J) were used for susceptibility studies. Drug interactions were assessed by checkerboard assays using the NCCLS M38-P microdilution methodology (8) after 24 h of incubation in standard 96-well sterile flat-bottom polystyrene plates (Corning). The final concentrations of the antifungal agents ranged from 0.008 to 128 µg/ml for caspofungin and from 0.03 to 2 µg/ml for itraconazole. Each well received 100 µl of the diluted drug concentrations. Dilutions were made in RPMI 1640 medium containing 0.165 M MOPS (morpholinepropanesulfonic acid) buffer at pH 7.0. Conidial inocula were counted with a hemocytometer, prepared at a concentration of 2.5 x 10⁴ CFU/ml in RPMI 1640-0.165 M MOPS, pH 7.0, and added at 100 µl/well (final volume of each well, conidia, and drugs, 200 µl). The MIC was the lowest drug concentration resulting in complete inhibition of hyphal growth (2). The MEC was the lowest drug concentration resulting in aberrant hyphal growth, as previously described (2). Plates were scanned both visually and microscopically with an inverted microscope at low (x40) magnification. The results were used to determine the fractional inhibitory concentration (FIC; in micrograms per milliliter) of the combination of caspofungin and itraconazole for each clinical isolate. FICs were calculated for both MIC and MEC end point measurements taken from the microwell with the lowest concentration of the drug combination needed to achieve the respective end points. The FIC of a drug for an individual isolate was calculated as the MIC or MEC of the drug when used in combination with another drug divided by the MIC or MEC of the drug when used alone. The FIC index (FICI) value was calculated by adding the FIC of caspofungin to the FIC of itraconazole for a particular isolate. FICI values were interpreted as follows: FICI 0.5, synergistic; 0.5 < FICI 1, synergistic to additive; 1 < FICI 4, indifferent; FICI > 4, antagonistic.

The MICs, MECs, and FICI values obtained for each of the isolates at 24 h are shown in Table 1. The MICs of caspofungin for A. fumigatus, A. flavus, and A. terreus (MIC 128 µg/ml) were at least two- to four-fold higher than that for A. niger (16 < MIC < 32). In contrast, MECs of caspofungin for all strains tested were similar (0.008 < MEC < 0.06 µg/ml), and all were far below the MICs. Both MICs and MECs of itraconazole for all 31 strains tested were similar (0.25 < MIC < 1; 0.03 < MEC < 0.5).

View this table: [in this window] [in a new window]

TABLE 1. MIC and FICI results for the Aspergillus spp. at 24 h

When FICIs were calculated by using MICs, caspofungin and itraconazole showed synergy for all A. fumigatus, A. flavus, and A. terreus strains (n = 25). For A. niger synergy or synergy to additivity was found in five strains and indifference was found in one (Table 2). In contrast, when FICIs were calculated by using MECs, no synergy (FICI 0.5) was observed for any of the strains. In five strains the combination showed synergy to additivity (among them four of six strains of A. terreus). For the majority of strains (26 of 31) the combination showed indifference (Table 2). Notably, antagonism was not detected in any of the strains tested by using either MIC or MEC end points.

View this table: [in this window] [in a new window]

TABLE 2. Overall results obtained for Aspergillus spp. at 24 h by using the two end points

In vitro and in vivo studies of caspofungin activity against Aspergillus using standard MIC methods and animal models resulted in some unusual observations. Arikan et al. (1) have shown that measurements of caspofungin MICs by NCCLS methods lead to very high values (MICs > 16 µg/ml). However, by using a microscopic end point of aberrantly growing hyphal tips, referred to as the MEC, values that were significantly lower than the MICs were obtained. The MECs correlated with a 50% reduction in turbidity in a microdilution assay and a prominent visual decrease in growth and were considered valid end points for assessment of caspofungin activity against Aspergillus.

In their rabbit model of aspergillosis, Petraitiene et al. (10) found that caspofungin treatment improved animal survival and reduced organism-mediated pulmonary injury. However, a paradoxical increase in CFU of Aspergillus per gram and an increased galactomannan antigen index in the successfully treated animals were observed. Thus, the correlation between in vitro and in vivo activity of caspofungin and the quantification of Aspergillus or its modified hyphae are problematic and difficult to interpret.

In our study, caspofungin MICs and MECs for Aspergillus spp. were in agreement with the findings of Arikan et al. (2). In their study they found synergy or synergy to additivity between caspofungin and amphotericin B against more than 50% of Aspergillus spp. tested by using MIC and MEC end points for their FICI analysis. There were no major discrepancies between FICI values found when MICs were used as end points and those found when MECs were used. In contrast, in our study, there was a significant difference between the FICI values depending on the end point used. Whereas MIC end points resulted in synergy for the majority of strains, MEC end points showed mainly indifference.

It is not clear which end point better predicts in vivo drug combination outcome. Preliminary studies using caspofungin and another azole derivative, voriconazole, showed in vitro synergy for 45.8% of 48 Aspergillus spp. tested and additivity for 41.6% (S. Perea, G. Gonzales, A. W. Fothergill, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson, Abstr. 101st Gen. Meet. Am. Soc. Microbiol, abstr. F-87, p. 372, 2001). In another in vitro study, using a radiometric assay and a growth inhibition end point, the combination of caspofungin and voriconazole showed additivity but not synergy (E. K. Manavathu, L. T. Ganesan, J. L. Cutright, and P. H. Chandrasekar, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. 125, 2001). In the only in vivo animal study reported, voriconazole was as effective as the combination with caspofungin in terms of survival; however, synergy was found when tissue fungal burden was assessed (6).

The mechanism explaining our findings of discrepancy in interpretation using MIC versus MEC end points is not clear. It might be speculated that, while low concentrations of caspofungin affect normal growth of Aspergillus, higher concentrations of the drug are needed to cause sufficient damage to the cell wall, thereby enabling itraconazole to confer its activity on the cell membrane of the organism at a lower concentration.

To further analyze the potential use of the above drug combination, it is imperative to perform an in vivo animal study of invasive aspergillosis assessing carefully the potential synergy or additivity of caspofungin and itraconazole. Only such studies will enable us to assess which in vitro study is more closely related to in vivo findings and what should be the recommendation for clinicians treating immunocompromised patients with invasive aspergillosis.

 
This work was supported by the Tel Aviv University startup seed money to N.O.

 
* Corresponding author. Mailing address: Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Ramat-Aviv 69978, Tel Aviv, Israel. Phone: 972-3-640-9599. Fax: 972-3-640-9160. E-mail: nosherov{at}post.tau.ac.il.

Top Abstract Text References

 

1
1. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.[Abstract/Free Full Text]
2
2. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.[Abstract/Free Full Text]
3
3. Franzot, S. P., and A. Casadevall. 1997. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 41:331-336.[Abstract]
4
4. Groll, A. H., and T. J. Walsh. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs 10:1545-1558.[CrossRef][Medline]
5
5. Hanson, L. H., and D. A. Stevens. 1989. Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens. Antimicrob. Agents Chemother. 33:1391-1392.[Abstract/Free Full Text]
6
6. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.[Abstract/Free Full Text]
7
7. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3,)-ß-D-glucan synthesis. Antimicrob. Agents Chemother. 38:1480-1489.[Abstract/Free Full Text]
8
8. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9
9. Perea, S., and T. F. Patterson. 2002. Invasive Aspergillus infections in hematologic malignancy patients. Semin. Respir. Infect. 17:99-105.[CrossRef][Medline]
10
10. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, R. L. Schaufele, A. Francesconi, J. Bacher, N. A. Avila, and T. J. Walsh. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, April 2003, p. 1416-1418, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1416-1418.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Mircus, G., Hagag, S., Levdansky, E., Sharon, H., Shadkchan, Y., Shalit, I., Osherov, N. (2009). Identification of novel cell wall destabilizing antifungal compounds using a conditional Aspergillus nidulans protein kinase C mutant. J Antimicrob Chemother 64: 755-763 [Abstract] [Full Text]  
• Cuenca-Estrella, M., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Gomez-Lopez, A., Buitrago, M. J., Mellado, E., Rodriguez-Tudela, J. L. (2008). In Vitro Activities of 35 Double Combinations of Antifungal Agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob. Agents Chemother. 52: 1136-1139 [Abstract] [Full Text]  
• Gonzalez, G. M., Gonzalez, G., Najvar, L. K., Graybill, J. R. (2007). Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model. J Antimicrob Chemother 60: 1341-1346 [Abstract] [Full Text]  
• Plummer, R., Bodkin, J., Power, D., Pantarat, N., Bubb, W. A., Kuchel, P. W., Sorrell, T. C. (2007). Effect of Caspofungin on Metabolite Profiles of Aspergillus Species Determined by Nuclear Magnetic Resonance Spectroscopy. Antimicrob. Agents Chemother. 51: 4077-4084 [Abstract] [Full Text]  
• Levdansky, E., Romano, J., Shadkchan, Y., Sharon, H., Verstrepen, K. J., Fink, G. R., Osherov, N. (2007). Coding Tandem Repeats Generate Diversity in Aspergillus fumigatus Genes. Eukaryot Cell 6: 1380-1391 [Abstract] [Full Text]  
• Cuenca-Estrella, M., Gomez-Lopez, A., Buitrago, M. J., Mellado, E., Garcia-Effron, G., Rodriguez-Tudela, J. L. (2006). In Vitro Activities of 10 Combinations of Antifungal Agents against the Multiresistant Pathogen Scopulariopsis brevicaulis.. Antimicrob. Agents Chemother. 50: 2248-2250 [Abstract] [Full Text]  
• Avis, I., Martinez, A., Tauler, J., Zudaire, E., Mayburd, A., Abu-Ghazaleh, R., Ondrey, F., Mulshine, J. L. (2005). Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator-Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth Inhibition. Cancer Res. 65: 4181-4190 [Abstract] [Full Text]  
• Cuenca-Estrella, M., Gomez-Lopez, A., Garcia-Effron, G., Alcazar-Fuoli, L., Mellado, E., Buitrago, M. J., Rodriguez-Tudela, J. L. (2005). Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49: 1232-1235 [Abstract] [Full Text]  
• Singh, N., Paterson, D. L. (2005). Aspergillus Infections in Transplant Recipients. Clin. Microbiol. Rev. 18: 44-69 [Abstract] [Full Text]  
• Markovich, S., Yekutiel, A., Shalit, I., Shadkchan, Y., Osherov, N. (2004). Genomic Approach to Identification of Mutations Affecting Caspofungin Susceptibility in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 48: 3871-3876 [Abstract] [Full Text]  
• Yekutiel, A., Shalit, I., Shadkchan, Y., Osherov, N. (2004). In Vitro Activity of Caspofungin Combined with Sulfamethoxazole against Clinical Isolates of Aspergillus spp.. Antimicrob. Agents Chemother. 48: 3279-3283 [Abstract] [Full Text]  
• Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
• Dannaoui, E., Lortholary, O., Dromer, F. (2004). In Vitro Evaluation of Double and Triple Combinations of Antifungal Drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48: 970-978 [Abstract] [Full Text]  
• Imhof, A., Balajee, S. A., Marr, K. A. (2003). New Methods To Assess Susceptibilities of Aspergillus Isolates to Caspofungin. J. Clin. Microbiol. 41: 5683-5688 [Abstract] [Full Text]  
• Serena, C., Ortoneda, M., Capilla, J., Pastor, F. J., Sutton, D. A., Rinaldi, M. G., Guarro, J. (2003). In Vitro Activities of New Antifungal Agents against Chaetomium spp. and Inoculum Standardization. Antimicrob. Agents Chemother. 47: 3161-3164 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shalit, I. Articles by Osherov, N. Search for Related Content PubMed PubMed Citation Articles by Shalit, I. Articles by Osherov, N.